New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareNAD+ vs Thymosin Beta-4

NAD+ vs Thymosin Beta-4

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
NAD+
Recovery & RepairAnti-Aging & Longevity
Thymosin Beta-4
Summary
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in all living cells that declines dramatically with age. It is critical for energy metabolism, DNA repair, and sirtuin activation. IV and subcutaneous NAD+ supplementation is used in anti-aging protocols and addiction recovery programs.
Thymosin Beta-4 is an endogenous 43-amino acid peptide that is the primary intracellular actin sequestering peptide. It promotes tissue repair, reduces inflammation, regenerates hair follicles, and protects cardiac tissue. Closely related to TB-500 (the active fragment), it is used for systemic tissue recovery and anti-aging.
Half-Life
Varies by route; IV provides direct cellular delivery
Not well characterized; likely similar to TB-500 (~1–2 hours)
Admin Route
IV, SubQ, Oral
SubQ, IM
Research
Typical Dose
500–1000 mg
5–10 mg
Frequency
Daily for 4–10 days (loading), then monthly maintenance
2x per week (loading), then 1x per week (maintenance)
Key Benefits
  • Restored cellular energy production (ATP)
  • Sirtuin activation for longevity and metabolic regulation
  • Enhanced DNA repair capacity
  • Improved mitochondrial function and biogenesis
  • Cognitive clarity and mental energy
  • Reduced inflammation
  • Addiction withdrawal support (opioids, alcohol, benzodiazepines)
  • Improved sleep quality
  • Enhanced athletic endurance
  • Systemic tissue repair and regeneration
  • Promotes cardiac recovery after myocardial infarction
  • Hair follicle regeneration and anti-hair-loss
  • Anti-inflammatory (systemic)
  • Wound healing acceleration
  • Neuroprotection after brain injury
  • Protects against ischemia-reperfusion injury
  • Anti-aging at cellular level
  • Synergizes powerfully with BPC-157
Side Effects
  • Flushing and warmth during IV infusion
  • Nausea during rapid IV administration
  • Chest tightness (from rapid infusion — slow the rate)
  • Injection site irritation (subcutaneous)
  • +1 more
  • Generally very well tolerated
  • Injection site reactions
  • Mild fatigue at initiation (repair signaling)
  • Rare: mild inflammatory response
  • +1 more
Stacks With